Alexion's cash cow receives label expansion; Matthew Dallas tapped to CFO post at Zealand Pharma
→ Back in June, Alexion‘s cash cow Soliris scored an additional FDA OK for the treatment of neuromyelitis optica spectrum disorder (NMOSD) — and today the drug was waved for a label expansion by the European Commission (EC).
The EC based its approval on results from the Phase III randomized, double-blind, placebo-controlled PREVENT study and long-term extension study (ECU-NMO-302) — with the latter still underway. “The study met its primary endpoint of prolonging the time to first adjudicated relapse and reducing the risk of relapse. Per the data, 98% of adult AQP4 antibody-positive patients treated with Soliris were relapse-free compared to 63% receiving placebo at 48 weeks,” read a press release.
A supplemental NDA for the drug is being reviewed in Japan and the drug enjoys orphan drug designation for the treatment of NMOSD in the US, the EU and Japan.
Last week, rumors cropped up that Alexion faced a possible buyout from Amgen, but those were squashed when Amgen swooped in with a $13.4 billion deal to pluck Celgene‘s blockbuster Otezla on Monday.
→ After wooing Alnylam exec Emmanuel Dulac to the post of CEO in April, Zealand Pharma has finally found a successor in Matthew Dallas for their CFO Mats Blom — who announced his departure in January. Dallas has served in the same role at Aveo Pharmaceuticals and CoLucid Pharmaceuticals (acquired by Eli Lilly). Dallas has also held stints at Genzyme, NEN Life Science Products and Kimberly Clark. Ivan Møller, who has been serving as interim CFO, will resume his role as SVP of technical development & operations.